• Je něco špatně v tomto záznamu ?

Endothelin type A receptor blockade attenuates aorto-caval fistula-induced heart failure in rats with angiotensin II-dependent hypertension

P. Kala, O. Gawrys, M. Miklovič, Z. Vaňourková, P. Škaroupková, Š. Jíchová, J. Sadowski, E. Kompanowska-Jezierska, A. Walkowska, J. Veselka, M. Táborský, H. Maxová, I. Vaněčková, L. Červenka

. 2023 ; 41 (1) : 99-114. [pub] 20221007

Jazyk angličtina Země Anglie, Velká Británie

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc22032067

OBJECTIVE: Evaluation of the effect of endothelin type A (ET A ) receptor blockade on the course of volume-overload heart failure in rats with angiotensin II-dependent hypertension. METHODS: Ren-2 renin transgenic rats (TGR) were used as a model of hypertension. Heart failure was induced by creating an aorto-caval fistula (ACF). Selective ET A receptor blockade was achieved by atrasentan. For comparison, other rat groups received trandolapril, an angiotensin-converting enzyme inhibitor (ACEi). Animals first underwent ACF creation and 2 weeks later the treatment with atrasentan or trandolapril, alone or combined, was applied; the follow-up period was 20 weeks. RESULTS: Eighteen days after creating ACF, untreated TGR began to die, and none was alive by day 79. Both atrasentan and trandolapril treatment improved the survival rate, ultimately to 56% (18 of 31 animals) and 69% (22 of 32 animals), respectively. Combined ACEi and ET A receptor blockade improved the final survival rate to 52% (17 of 33 animals). The effects of the three treatment regimens on the survival rate did not significantly differ. All three treatment regimens suppressed the development of cardiac hypertrophy and lung congestion, decreased left ventricle (LV) end-diastolic volume and LV end-diastolic pressure, and improved LV systolic contractility in ACF TGR as compared with their untreated counterparts. CONCLUSION: The treatment with ET A receptor antagonist delays the onset of decompensation of volume-overload heart failure and improves the survival rate in hypertensive TGR with ACF-induced heart failure. However, the addition of ET A receptor blockade did not enhance the beneficial effects beyond those obtained with standard treatment with ACEi alone.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc22032067
003      
CZ-PrNML
005      
20230131150942.0
007      
ta
008      
230120s2023 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1097/HJH.0000000000003307 $2 doi
035    __
$a (PubMed)36204993
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Kala, Petr $u Center for Experimental Medicine, Institute for Clinical and Experimental Medicine $u Department of Cardiology, University Hospital Motol and 2nd Faculty of Medicine, Charles University, Prague, Czech Republic
245    10
$a Endothelin type A receptor blockade attenuates aorto-caval fistula-induced heart failure in rats with angiotensin II-dependent hypertension / $c P. Kala, O. Gawrys, M. Miklovič, Z. Vaňourková, P. Škaroupková, Š. Jíchová, J. Sadowski, E. Kompanowska-Jezierska, A. Walkowska, J. Veselka, M. Táborský, H. Maxová, I. Vaněčková, L. Červenka
520    9_
$a OBJECTIVE: Evaluation of the effect of endothelin type A (ET A ) receptor blockade on the course of volume-overload heart failure in rats with angiotensin II-dependent hypertension. METHODS: Ren-2 renin transgenic rats (TGR) were used as a model of hypertension. Heart failure was induced by creating an aorto-caval fistula (ACF). Selective ET A receptor blockade was achieved by atrasentan. For comparison, other rat groups received trandolapril, an angiotensin-converting enzyme inhibitor (ACEi). Animals first underwent ACF creation and 2 weeks later the treatment with atrasentan or trandolapril, alone or combined, was applied; the follow-up period was 20 weeks. RESULTS: Eighteen days after creating ACF, untreated TGR began to die, and none was alive by day 79. Both atrasentan and trandolapril treatment improved the survival rate, ultimately to 56% (18 of 31 animals) and 69% (22 of 32 animals), respectively. Combined ACEi and ET A receptor blockade improved the final survival rate to 52% (17 of 33 animals). The effects of the three treatment regimens on the survival rate did not significantly differ. All three treatment regimens suppressed the development of cardiac hypertrophy and lung congestion, decreased left ventricle (LV) end-diastolic volume and LV end-diastolic pressure, and improved LV systolic contractility in ACF TGR as compared with their untreated counterparts. CONCLUSION: The treatment with ET A receptor antagonist delays the onset of decompensation of volume-overload heart failure and improves the survival rate in hypertensive TGR with ACF-induced heart failure. However, the addition of ET A receptor blockade did not enhance the beneficial effects beyond those obtained with standard treatment with ACEi alone.
650    _2
$a krysa rodu Rattus $7 D051381
650    _2
$a zvířata $7 D000818
650    _2
$a angiotensin II $7 D000804
650    _2
$a receptor endotelinu A $7 D044022
650    _2
$a atrasentan $7 D000077868
650    12
$a hypertenze $x komplikace $x farmakoterapie $7 D006973
650    _2
$a inhibitory ACE $x farmakologie $7 D000806
650    12
$a srdeční selhání $x farmakoterapie $x etiologie $7 D006333
650    _2
$a potkani transgenní $7 D055647
650    12
$a píštěle $7 D005402
650    _2
$a endoteliny $7 D016232
650    _2
$a endotelin-1 $7 D019332
650    _2
$a receptor angiotensinu typ 1 $7 D044140
655    _2
$a časopisecké články $7 D016428
700    1_
$a Gawrys, Olga $u Center for Experimental Medicine, Institute for Clinical and Experimental Medicine $u Department of Renal and Body Fluid Physiology, Mossakowski Medical Research Institute, Polish Academy of Science, Warsaw, Poland
700    1_
$a Miklovič, Matúš $u Center for Experimental Medicine, Institute for Clinical and Experimental Medicine
700    1_
$a Vaňourková, Zdenka $u Center for Experimental Medicine, Institute for Clinical and Experimental Medicine
700    1_
$a Škaroupková, Petra $u Center for Experimental Medicine, Institute for Clinical and Experimental Medicine
700    1_
$a Jíchová, Šárka $u Center for Experimental Medicine, Institute for Clinical and Experimental Medicine
700    1_
$a Sadowski, Janusz $u Department of Renal and Body Fluid Physiology, Mossakowski Medical Research Institute, Polish Academy of Science, Warsaw, Poland
700    1_
$a Kompanowska-Jezierska, Elzbieta $u Department of Renal and Body Fluid Physiology, Mossakowski Medical Research Institute, Polish Academy of Science, Warsaw, Poland
700    1_
$a Walkowska, Agnieszka $u Department of Renal and Body Fluid Physiology, Mossakowski Medical Research Institute, Polish Academy of Science, Warsaw, Poland
700    1_
$a Veselka, Josef $u Department of Cardiology, University Hospital Motol and 2nd Faculty of Medicine, Charles University, Prague, Czech Republic
700    1_
$a Táborský, Miloš $u Department of Internal Medicine I, Cardiology, University Hospital Olomouc and Palacký University, Olomouc
700    1_
$a Maxová, Hana $u Department of Pathophysiology, 2nd Faculty of Medicine, Charles University
700    1_
$a Vaněčková, Ivana $u Institute of Physiology of the Czech Academy of Sciences, Prague, Czech Republic
700    1_
$a Červenka, Luděk $u Center for Experimental Medicine, Institute for Clinical and Experimental Medicine $u Department of Internal Medicine I, Cardiology, University Hospital Olomouc and Palacký University, Olomouc
773    0_
$w MED00002723 $t Journal of hypertension $x 1473-5598 $g Roč. 41, č. 1 (2023), s. 99-114
856    41
$u https://pubmed.ncbi.nlm.nih.gov/36204993 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20230120 $b ABA008
991    __
$a 20230131150938 $b ABA008
999    __
$a ok $b bmc $g 1891066 $s 1183402
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2023 $b 41 $c 1 $d 99-114 $e 20221007 $i 1473-5598 $m Journal of hypertension $n J Hypertens $x MED00002723
LZP    __
$a Pubmed-20230120

Najít záznam

Citační ukazatele

Pouze přihlášení uživatelé

Možnosti archivace